Please select the option that best describes you:
Would you consider circulating DNA assay in resected node-negative deficient MMR colon cancer off-trial to guide your treatment?
Answer from: Medical Oncologist at Academic Institution
Hello. It appears you are asking about a stage II MMR deficient/MSI-High colon cancer. The recurrence rate for stage II mismatch repair deficient (dMMR) colon cancer is generally lower than that for mismatch repair proficient (pMMR) tumors. Studies have shown that the 5-year recurrence rate for stag...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I do not use ctDNA in these cases outside of a clinical trial. The predictive ability of ctDNA has not been confirmed (yet). A recent study (COBRA) was halted early because it met its pre-specified stopping rules. COBRA was a phase II/III study designed to compare 2 adjuvant treatment strategies in ...
Answer from: Medical Oncologist at Community Practice
Yes, I would offer baseline ctDNA and monitoring if the patient understands it could change the cadence of scans and perhaps increase the chance for early (curative) surgery. This assumes they have at least a 5-year expected baseline survival and would be a surgical candidate, etc.
Answer from: Medical Oncologist at Community Practice
Updated 5-year results from the DYNAMIC study of stage II colon cancer who were randomized to either ctDNA-guided management or standard management showed that recurrence free survival (RFS) rates were 88% and 87% and 5-year overall survival (OS) rates were 93.8% and 93.3% for ctDNA-guided versus st...
Answer from: Medical Oncologist at Academic Institution
The analysis by Dr. @Copur is quite nuanced and recognizes many of the issues here. In addition, the combined analysis by Dan Sargent from the ACCENT data base suggested use of 5FU may be detrimental for MMRd colon cancer (Sargent et al., JCO 2014 and previous) but in the end, concluded that the pro...